Portfolio Comments (0) 03 May 2012

Biotechnology company
with leading therapies

This company has developed leading anti-infective therapies, one of which has achieved completely successful Phase 1 (safety) and Phase 2a (dosing) clinical trial results. The company has just completed an interim funding until major funding is secured from VCs and/or licensors.The bridging funds are needed partly to enable the company to continue advancing its drug development and partly to give it sufficient working capital to secure one or more licence deals and to enable it to carry out a Phase 2b trial in the US.

Terms for the present interim funding round are attractive when set against estimates of the company’s valuation.

Click here for full details and update (available for Members of Aurora Private Equity only).

Register today for free updates of new opportunities
  • Use the Aurora Network to contact growing companies
  • Offer your professional help as executive or director
  • See new investment opportunities in high growth companies
  • We will never pass your details to other lists without your permission
Be part of the economic revival Ask us anything in confidence
Invest £1k, £10k, or £100k
  • Invest in high growth, interesting and well-researched companies
  • Aim for 3x to 10x return from your investment
  • Putting some of your investment funds into high growth businesses can make sense during difficult economic times
  • Choose whether to invest at all and how much with Aurora
  • Join Aurora Private Equity and make your funds grow
Be an angel, be part of it Ask us anything in confidence